Navigation Links
Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal
Date:5/19/2009

ts with major unipolar depressive disorder (MDD).

The results of primary efficacy end point analyses demonstrated consistent statistical superiority of Labopharm's trazodone formulation over placebo. Moreover, statistically significant improvements were demonstrated on several secondary efficacy end points, including Hamilton Rating Scale for Depression (HAMD-17) responders, Montgomery-Asberg Depression Rating Scale (MADRS) score, and quality of sleep.

The authors emphasize the clinical importance of targeting sleep improvement in patients with MDD, which is reported in more than 90% of cases. Patients receiving Labopharm's trazodone formulation demonstrated significant improvements versus placebo in all three quality of sleep end points, with an improvement by the first week of therapy in "overall quality of sleep" and "awakening during the night".

Agitation is a common symptom of MDD and patients taking antidepressants often experience an exacerbation of this symptom. In the study, those administered Labopharm's trazodone formulation showed no increase in agitation.

The results of the study demonstrate Labopharm's once-daily trazodone may have a early onset of action. The overall antidepressant efficacy of Labopharm's trazodone formulation was accompanied by improvements early in the study, including an early improvement in HAMD-17 scores, which suggest that patients may see clinical benefit within the first 2 weeks of treatment, and a significantly greater number of HAMD-17 responders than placebo by the end of titration.

Adverse events of particular concern in the treatment of MDD are those related to weight gain and sexual dysfunction, as they are among the most prevalent reasons for discontinuation of antidepressant therapy. In the study, there were no significant changes in body weight in either those administered Labopharm's trazodone formulation or those administered placebo and there was a low incidence of sexual dy
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. International Isotopes Inc. Announces First Quarter 2009 Financial Results
2. Encision Reports Fourth Quarter and Fiscal Year 2009 Results
3. Uroplasty to Issue Fourth Fiscal Quarter and Full Year Results on June 4, 2009
4. BMP Sunstone Reports First Quarter 2009 Financial Results
5. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
6. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
7. Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 2009
8. AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results
9. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
10. Derma Sciences Reports First Quarter 2009 Results
11. NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... initiate a range of care management programs for people living ... room (ER) use, improved health and lower costs. The ... (ACHP), are part of a report that is a comprehensive ... to improve care. Care management is the coordination ...
... Factors for,Developing MS, UB Study Shows, Summary: ... (CCSVI), which has attracted global attention as possibly being correlated ... the presence of risk factors in subjects who do not ... of 252 volunteers has found an association between CCSVI and ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... fiddling with food and drink or doing some last-minute grooming, ... admit to being dangerously distracted while behind the wheel, a ... Interactive/HealthDay poll, most adults who drive on a regular ...
... or respirators put health care workers at risk of 2009 ... in the U.S., according to a study published in the ... the journal of the Society of Healthcare Epidemiology of America. ... Disease Control and Prevention (CDC), tracked 63 Southern California health ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- Women with lobular ... other forms of breast cancer to have a father who ... Swedish researchers examined the family history, pathology reports and hospital ... 2008. About 40 percent of the women had invasive ductal ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- About 40 percent ... before high school, which suggests that suicidal thoughts and behavior ... new study. As part of an ongoing survey, University ... or 19, about their history of suicide attempts. Nearly ...
Cached Medicine News:Health News:New report: Community health plans improving care for patients with chronic illnesses 2Health News:New report: Community health plans improving care for patients with chronic illnesses 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 2Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 4Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 2Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 3Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 4Health News:Lobular Breast Cancer Linked to Paternal Cancer History 2Health News:Many Suicidal Teens Make First Try Before High School 2
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer ... protective stent system, today announced another positive study, reinforcing MGuard,s ... evaluation by Drs. Dmitry Dratva, Yaron Almagor, Jonathan Balkin, David ... Department of Cardiology at Shaare Zedek Medical ...
... SpeechTrans, a leader in app-based multi-language translation, ... Impaired. The new app enables the hearing impaired to ... Italian and German and Mandarin Chinese without the need ... With the new app, each person can simply speak ...
Cached Medicine Technology:Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 2Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 3Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 4Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 5Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 6SpeechTrans Offers Mobile Translation App for Hearing Impaired 2
... & Lomb PMMA Anterior Chamber Intraocular Lenses ... aphakia in patients 60 years of age ... been removed by primary intracapsular cataract extraction; ... is a structural reason that the anterior ...
... STAARVISC II is a sterile nonpyrogenic, transparent ... STAARVISC II contains 12 mg/ml of high ... sodium hyaluronate dissolved in physiological saline. In ... viscosity is 105,000 cps (105 Pa s) ...
... Methylcellulose solution that is especially well suited ... incision surgery. The low molecular weight of ... minimal risk of elevated intraocular pressure. The ... of the surgical field throughout capsulorhexis and ...
... AMO Vitrax features a low ... protection and viscosity you need ... phaco and small-incision surgery. The ... anterior chamber depth for safe, ...
Medicine Products: